By Keith Goldberg ( June 29, 2012, 4:28 PM EDT) -- Results from a study on GlaxoSmithKline PLC's anti-nausea drug Zofran and its generic equivalents suggest that some intravenous use may affect the heart's electrical activity, leading to patients developing an abnormal, potentially fatal heart rhythm, the U.S. Food and Drug Administration said Friday....
Law360 is on it, so you are, too.
A Law360 subscription puts you at the center of fast-moving legal issues, trends and developments so you can act with speed and confidence. Over 200 articles are published daily across more than 60 topics, industries, practice areas and jurisdictions.
A Law360 subscription includes features such as
- Daily newsletters
- Expert analysis
- Mobile app
- Advanced search
- Judge information
- Real-time alerts
- 450K+ searchable archived articles
And more!
Experience Law360 today with a free 7-day trial.